INTRODUCING
NEW LOOK!
VOLUME 29 ISSUE 2
FALL/WINTER 2023

The Myelodysplastic Syndromes Foundation, Inc.

THANK YOU 2023!
We met our fundraising goal of $400k, stay tuned for 2024.

Move FOR MDS
Community Walks to Drive Awareness & Accelerate Research

In This Issue

PATIENTS & FAMILIES SECTION
2 Know Your MDS Subtype, IPSS-M Score and Gene Mutation Profile
3 Move for MDS 2023
6 Our Patient Stories
9 MDS Patient Events
10 Journey of Empowerment (JOE)
12 Clinical Care Options
16 MDS Foundation
19 MDS Patient and Caregiver Survey

PROFESSIONAL SECTION

Meeting Highlights & Announcements
24 Summary: 17th International Congress on MDS
26 3rd Regional Symposium on MDS – Japan
27 ASH 2023: Friday Satellite Symposium
28 MDS Foundation Leadership

Research
29 MDS Risk Assessment Tools
30 MDS Centers of Excellence
36 Press Releases
39 MDSF Quarterly Interactive Metrics

PLAN TO ATTEND

18th INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES
7 – 10 May 2025, Rotterdam, The Netherlands

WWW.MDS-FOUNDATION.ORG
Do you know...

Do You Know Your MDS Subtype, IPSS- M Score & Gene Mutation Profile?

MDS treatment is individualized based on a patient’s subtype, IPSS-M score and, to some extent, genetic mutations. This knowledge will empower patients and their caregivers to take a more active role in decisions about their treatment and advocate for appropriate treatments that may prolong their life and improve their quality of life. The following information is designed to help you understand how your subtype and IPSS-M score are determined, as well as general information on genetic mutations commonly found in MDS and the importance of genetic testing for these mutations.

Knowing your subtype, IPSS-M score and gene mutation profile will help facilitate discussions with your healthcare provider on what this means for you personally and help select the best treatment options.

IPSS-M Score
The IPSS-M is a classification system used by doctors to help predict a person’s risk of developing AML and overall survival without treatment.

MDS Subtype
MDS is classified into several different subtypes based on the following features: Blood cell counts, percentage of blasts in the bone marrow, and Cytogenetics.

Mutation Profile
Genetic mutations occur when a gene is damaged and alters the genetic message. Mutations can potentially identify effective therapies to treat your disease.

Visit Our Microsite
Understanding Your MDS: Know Your Score, Your Subtype, And Your Mutation

This brochure is intended to help you better understand the diagnosis of MDS. Created by the MDS Foundation staff, Board of Directors, and medical and scientific leaders, it will explain the various MDS subtypes; how a prognostic scoring system is designed and where you can place yourself with the help of your physician and other health professionals. You will learn about normal and abnormal blood cells; leukemic blasts; blood counts; chromosomes and molecular mutations that may assist your provider in further modifying your subtype and, possibly, selecting the type of therapy for you.

John M. Bennett, MD
First Chair and Founding Member of the MDS Foundation

To learn more, visit our website at https://www.mdsknowledgeispower.com/.

To order your free copy of UNDERSTANDING YOUR MDS: Know your Score, your Subtype, and your Mutation, please call 1-609-298-1035 or scan the QR code.

Bone Marrow Blast
MDS–RS–MLD
Cytogenetics

To learn more, visit our website at https://www.mdsknowledgeispower.com/.
Community Walks to Drive Awareness & Accelerate Research

Ready for 2024?
Stay tuned to find out next year’s locations!

Clinical Trials in MDS
New modules coming soon to YouAndMDS.com

Developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
Questions about MDS? Need support or resources?

Contact our Director of Patient Care now.

You are not on your own. The MDS Foundation supports and educates patients, communities and healthcare providers. We help accelerate innovative research in MDS and its related diseases to better diagnose, control and ultimately cure them. We can help you. We are the people who make hope work.

Educate • Communicate • Advocate

Ashley Moncrief RN, BSN, Director of Patient Care:
1-800-637-0839 ext. 210 • amoncrief@mds-foundation.org

mds-foundation.org
Find MDS Clinical Trials Across the US

Using the NEW MDS Clinical Trial Matching Platform

The Clinical Trial Process

Identification | Screening | Enrollment | Treatment | Follow-Up

The MDS Foundation is proud to partner with SparkCures, LLC to develop a Clinical Trail Matching Platform. This revolutionary platform will offer fast and personalized clinical trial screening and matching services, simplifying the complex landscape of clinical trial options for MDS patients, caregivers, and healthcare providers.

For more information visit https://mdsf.sparkcures.com/
The Diagnosis

Indisputable evidence – “Sorry Mrs. White, but your biopsy shows that you have MDS.”

No primer on MDS, no 30-minute explanation of a disease so complicated that I can’t even pronounce its ‘proper name,’ no ‘I know that this is difficult, but…’

Everyone’s tale is a bit different, but in my case, it began there and whatever came next in the 10 minutes my husband and I had with the doctor sounded like: ‘sorry… blah, blah, blah… low risk… blah, blah, blah… yes, it’s considered a cancer… blah, blah, blah… unfortunately no cure… blah, blah, blah… you could try a stem cell transplant but… blah, blah, blah…’

The Aftermath

Where would we be without Dr. Google, and I’m being completely facetious. It might be a rare disease but there is plenty of information to send you into the land of anxiety, panic, fear, and hopelessness. We’ve all been there, but the first question is: ‘how long do I have?’ and that is not the question to ask. I promise. So, with little to no understanding about my particular situation, I began a deep dive into the rabbit hole and stayed down there long enough to get very depressed.

The Remedy (not recommended)

I could have spared myself a great deal of angst if I had known what I know now, but I was out there on my own. My first inclination was to shut down: everyday, after work, I would come home and binge on episode after episode of The Office. This was my way of numbing my brain and escaping whatever fears and anxieties I had allowed into my head. It was not the worst coping strategy, but after 9 seasons, I began to wake up to a new reality. This was going to be my life and I better get going.

A Better Remedy

During this time, I was being monitored by my doctor at the VA Cancer Center, and I was beginning to come out of the fog. My first step was to clear my head, so to speak, and I found a wonderful therapist who deals specifically with grief.

And if MDS was my disease, grief was one of its manifestations. I worked hard to get my head around it, and then even harder to find it a place in my life, a place where it wouldn’t get in the way of the life I had left.

No Control, No Way

When my GP (general practitioner) advised me that this was a disease that I had no control over, she had basically thrown down a gauntlet. Yes, I understood that this was an incurable disease and there was nothing I could do to change the inevitable – that was up to the specialists and medications. But if she thought that someone like me, whose middle name is CONTROL, was going to sit back and let this run its course, well she was mistaken. I had already found the healthy tools to deal with the anxiety and depression, and now I was going to work on the other challenges that MDS brings to the table. The easy things: diet, exercise, and sleep. The harder things: fatigue, letting things go and letting people in.

Talk is Cheap

My GP is a gem, and her words weren’t meant to hurt. She gave me even better advice: talk is cheap. So, I began talking and listening. MDS is a rare disease, but there are so many smart people out there working on it – worldwide. And, finally, the internet became my ally as I began some serious research and discussion and second opinions. I went to Johns Hopkins. I went to Dana Farber and contacted folks ‘in the know.’ All concluded that my course of treatment was the one that they would recommend, and I felt more in control than ever before. I’ve also realized that what works for me may not work for all, so I will avoid a discussion of my ‘course of action.’ I will say this: when one thing stops working, there are more things to try and try we must.

The Land of MDS

We come to the land of MDS via many routes: bruising, bleeding, fatigue, infections, rashes, shortness of breath, odd results on a routine blood test, an astute doctor tells you “do you know you are yellow?, ” as well as indisputable evidence via blood tests or a bone marrow biopsy.

THE DIAGNOSIS

Indisputable evidence – “Sorry Mrs. White, but your biopsy shows that you have MDS.”

No primer on MDS, no 30–minute explanation of a disease so complicated that I can’t even pronounce its ‘proper name,’ no ‘I know that this is difficult, but…’

Everyone’s tale is a bit different, but in my case, it began there and whatever came next in the 10 minutes my husband and I had with the doctor sounded like: ‘sorry… blah, blah, blah… low risk… blah, blah, blah… yes, it’s considered a cancer… blah, blah, blah… unfortunately no cure… blah, blah, blah… you could try a stem cell transplant but… blah, blah, blah…’

THE AFTERMATH

Where would we be without Dr. Google, and I’m being completely facetious. It might be a rare disease but there is plenty of information to send you into the land of anxiety, panic, fear, and hopelessness. We’ve all been there, but the first question is: ‘how long do I have?’ and that is not the question to ask. I promise. So, with little to no understanding about my particular situation, I began a deep dive into the rabbit hole and stayed down there long enough to get very depressed.

THE REMEDY (not recommended)

I could have spared myself a great deal of angst if I had known what I know now, but I was out there on my own. My first inclination was to shut down: everyday, after work, I would come home and binge on episode after episode of The Office. This was my way of numbing my brain and escaping whatever fears and anxieties I had allowed into my head. It was not the worst coping strategy, but after 9 seasons, I began to wake up to a new reality. This was going to be my life and I better get going.

A BETTER REMEDY

During this time, I was being monitored by my doctor at the VA Cancer Center, and I was beginning to come out of the fog. My first step was to clear my head, so to speak, and I found a wonderful therapist who deals specifically with grief.

And if MDS was my disease, grief was one of its manifestations. I worked hard to get my head around it, and then even harder to find it a place in my life, a place where it wouldn’t get in the way of the life I had left.

NO CONTROL, NO WAY

When my GP (general practitioner) advised me that this was a disease that I had no control over, she had basically thrown down a gauntlet. Yes, I understood that this was an incurable disease and there was nothing I could do to change the inevitable – that was up to the specialists and medications. But if she thought that someone like me, whose middle name is CONTROL, was going to sit back and let this run its course, well she was mistaken. I had already found the healthy tools to deal with the anxiety and depression, and now I was going to work on the other challenges that MDS brings to the table. The easy things: diet, exercise, and sleep. The harder things: fatigue, letting things go and letting people in.

TALK IS CHEAP

My GP is a gem, and her words weren’t meant to hurt. She gave me even better advice: talk is cheap. So, I began talking and listening. MDS is a rare disease, but there are so many smart people out there working on it – worldwide. And, finally, the internet became my ally as I began some serious research and discussion and second opinions. I went to Johns Hopkins. I went to Dana Farber and contacted folks ‘in the know.’ All concluded that my course of treatment was the one that they would recommend, and I felt more in control than ever before. I’ve also realized that what works for me may not work for all, so I will avoid a discussion of my ‘course of action.’ I will say this: when one thing stops working, there are more things to try and try we must.
**My Experience with the MDS Foundation**

Suresh Dutia  
Vienna, VA

**I experienced a drastic drop in my platelets after the COVID Booster.**

Following several blood tests & a bone marrow biopsy, I was diagnosed with low-grade myelodysplastic syndrome (MDS) mainly affecting platelets. I started searching for more information online and stumbled upon the MDS Foundation Website. After reviewing information, I contacted Ms. Ashley Moncrief, Director of Patient Care, and explained my case and all relevant test results. With the help of Ms. Moncrief, I was immediately connected with MDS Center of Excellence at Johns Hopkins University School of Medicine. This experience alleviated my anxiety about MDS and rendered moral upliftment & positive feelings to deal with my health. My overall experience with the MDS Foundation is excellent. Further, I also reviewed information on the MDS Foundation website in various Languages, and it is very impressive.

---

**A LONELY DISEASE**

MDS is an exclusive disease. ‘You have WHAT? Never heard of it.’ Yes, most haven’t. We are exclusive, but that is not a good thing. It’s a complicated disease, it’s a rare disease, and it is a lonely disease. Support groups are not in every city, and you won’t meet many people in your world that have come into contact with the disease, much less know a fellow traveler. Organizations like the MDS Foundation are invaluable for patients wanting a bit of connection and support and information. Infusion rooms are not filled with MDS sufferers, but they are filled with people facing challenges and their determination and hopeful outlooks and faith and good cheer (not to mention the nurses and doctors who are on your team) remind me that this may be what they mean by ‘God closes a door, but he opens a window.’

**A BLESSING (WELL, SORT OF)**

I won’t kid myself or you. If I could shuck this disease, I would in a red-hot second. But, that is not an option so let me tell you a few good things that have happened. I love my life, now more than ever. I’ve prioritized my relationships, and I don’t miss an opportunity to connect with the people I love. I’m not in a hurry and I don’t fret when things go wrong (well, that’s a goal as we all know, waiting for the results of our latest biopsy or blood test or whatever measurement determines our next step.) I tend to say yes to most things. I take such joy in the smallest things. I’m beginning to relish those seemingly trite quotes you find on plaques and mugs and tee shirts: don’t sweat the small stuff, seize the day, everything happens for reason … you know them all. Whoever came up with them must have had some challenges! But, I don’t get bothered by small things. I do wake up every morning feeling grateful even though I feel crummy; I am grateful for everything in my life. I do avoid negativity when I can and I do live each day as it was my last. I’m sure that there are a few close to me that may call me out on a few of these, but hey, it’s my article!

**LAST WORDS**

MDS does not define me, therefore I try very hard not to let it into my daily life. There are few signs of the disease, and it’s easy for me not to make it front and center with family and friends. I’ve made that a priority: I know that I’m surrounded by love and support and could call on so many if I needed them. Bless them all.

As hard as I try not to burden with a ‘woe is me’ attitude, there are a few in my life that have shouldered the ‘bad side’ of this journey, and I’d be remiss in not thanking my incredibly supportive husband who has been with me since day one. We all have that person, and they all deserve recognition because not even I know what these past 5 years have done to his soul and spirit. I try to imagine if our situations were reversed, and I can’t. I can only hope that I would be as generous and supportive and patient. My goal has been NOT to let MDS define me as a person, as a victim; therefore, there are so many aspects of this disease that only he is aware of and I will be forever in his debt for helping me shoulder the challenge of MDS.
Hope doesn't work just by wishing. That’s important to know for fighting MDS, a challenging but little-known cancer that, left undetected, can progress to acute myeloid leukemia and other forms of blood cancer. MDS is not incurable. It simply hasn’t been cured yet. But with your help, that day is coming.

Your donation turns hope into reality. For nearly 30 years, The Myelodysplastic Syndromes Foundation has been a catalyst for progress: Supporting patients. Expanding education. Accelerating research. Bringing critical awareness of MDS to the world. We depend on your investment to make this progress happen. Donate today. And make hope a life-changing force. Give at MDSdonate.org
MDS Patient Forums/ Webinars/ Podcasts

COMING IN 2024...
Make sure to visit our website at WWW.MDS-FOUNDATION.ORG for news on upcoming events

UPCOMING MDS PATIENT FORUM, WEBINAR & PODCAST TOPICS WILL INCLUDE:

- Understanding the Genetics: Reading NGS Reports, IPSS-M, Targeted Therapies, Cytogenetics (Good vs. Poor Risk)
- Review of the WHO 2022 Classifications
- History of MDS Drug Approvals & Drug Classes for MDS
- Emotional Support: Role of Mental Health Professionals, Starting a Support Group, Caregiver Support
- Homeopathic Therapy
- Transfusion Basics: Purpose, Long Term Impact, Iron Chelation, Irradiated Products, Tracking
- Treatment Option Types: Watch & Wait, Curative (HSCT), Supportive Care, Disease Control, Palliative Care, Hospice
- Oncologic Emergencies in MDS & Infection Basics
- MDS Foundation Basics: Getting the Help you Need
- Professional Conference Patient Summaries & Clinical Trial News
- Being Your Own Advocate

IN-PERSON PATIENT EVENTS WILL BE RETURNING IN 2024

WANT TO HAVE A PATIENT FORUM NEAR YOU?
Reach out to our Director of Patient Care, Ashley (Amoncrief@mds-foundation.org), to advocate for a spot in your community!
JOE IS GETTING AN UPGRADE!

JOE in MDS, short for ‘Journey Of Empowerment’, launched in March 2023. Since then, we have listened to the insights provided by patients, caregivers, and healthcare professionals to improve the platform and enhance the learner experience.

We will be making updates to JOE in MDS throughout 2024, aligning the platform with the feedback we received from the MDS community.

New modules (including nutritional information)
More visuals and diagrams
Updated dashboard
Improving user experience
Resource section
New quiz questions
Content updates
Tailored learning

VISIT TODAY
mdsJOE.com

MDS JOE is brought to you by the MDS Foundation
GUIDE TO ASSISTANCE PROGRAMS IN THE UNITED STATES

We have assembled a listing of assistance programs available to MDS patients. It is important to know that there is support for those who cannot afford medicine or other healthcare costs. We hope this new resource will be beneficial in helping you with your medical needs.

PLANNED GIVING LEAVING A LEGACY...

WRITE THE MDSF INTO YOUR WILL

In addition to the gifts you give today and throughout your lifetime, taking the time to write MDSF into your will—or to make any other planned/estate gift—provides an enduring legacy of your personal interest and commitment to providing education, service, and research for those facing bone marrow failure diseases. Ask your attorney to include this paragraph, specified to your gift preferences, in your will:

I give, devise, and bequeath $_______ (amount) or _______% (percentage) to the MDS Foundation, 4573 South Broad Street, Suite 150, Yardville, NJ 08620, a not-for-profit corporation for its charitable uses as directed by its Board of Directors.

It is important to remember your friends and family when drawing up a will and to make sure that all loved ones are taken care of. Once you have done this, you may wish to leave a legacy to the MDS Foundation. Leaving a legacy to the MDS Foundation is one of the greatest gifts that you can give.
A diagnosis of Myelodysplastic Syndrome (MDS) is a shock to anyone. The MDS Foundation is here to support patients and their families as they navigate their care options. We provide information about the disease, work with healthcare providers, and fund research.

The MDS Foundation strives to learn from patients’ experiences. In partnership with Clinical Care Options, LLC., the MDS Foundation surveyed patients with MDS about their perceptions of treatment and care. The following results showcase patients’ concerns during the treatment process and what they would like from their care team. Together we are ensuring the patient voice is heard!

Understanding MDS and Treatment Options

MDS is a complex disease, taking many forms. The treatment options are just as varied and can be confusing. Survey results show that most patients have discussed multiple treatment options and diagnosis tools with their healthcare team.

<table>
<thead>
<tr>
<th>Therapies Care Team Discussed with Patient</th>
<th>Patients under 70</th>
<th>Patients over 70</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunosuppressive</td>
<td>21%</td>
<td>16%</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>68%</td>
<td>59%</td>
</tr>
<tr>
<td>Immunomodulator</td>
<td>25%</td>
<td>25%</td>
</tr>
<tr>
<td>Erythropoiesis-Stimulating Agents</td>
<td>43%</td>
<td>53%</td>
</tr>
<tr>
<td>Erythroid Maturation Agent</td>
<td>14%</td>
<td>16%</td>
</tr>
<tr>
<td>Stem Cell Transplant</td>
<td>86%</td>
<td>56%</td>
</tr>
<tr>
<td>Transfusion Support</td>
<td>71%</td>
<td>78%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk and Prognosis Tools Discussed with Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular/Genetic Mutations</td>
</tr>
<tr>
<td>IPSS-M</td>
</tr>
<tr>
<td>Genetic/Molecular/Biomarker Testing</td>
</tr>
<tr>
<td>Clinical Trials</td>
</tr>
</tbody>
</table>
PATIENT/FAMILY SECTION

In partnership with

Patients Comfort with Care Team
As a patient, being heard by your healthcare team is essential. Our findings show that most patients feel their needs and concerns are being met by their healthcare providers. Patients feel informed about treatment options and that their values and treatment goals are understood.

Feeling Understood

- 63% of patients feel their needs and goals are understood
- 81% of male patients felt understood compared to 52% of female patients

Well Informed and Appropriate Treatment

- 66% of patients feel well informed about treatment options
- 76% of patients feel their team provides appropriate treatments

Patient’s Most Important Treatment Goal

- Maintaining Quality of Life: 56%
- Prolonging Life: 31%
- Ensuring They are not a Burden on Loved Ones: 9%
- Minimizing Disease Symptoms: 4%

Accessibility and Cost of Care

When you are diagnosed with MDS, the last thing you want to think about is how to access treatment and the cost of care. Fortunately, most of the survey participants have easy access to care, and cost is a concern to less than half.

Concerns About Cost

- 39% of patients are concerned about the cost of care

Discussed Insurance or Financial Assistance

- 35% of patients discussed insurance costs and financial assistance
- 48% of patients discussed insurance costs and financial assistance

This survey was conducted by MDS Foundation in partnership with CCO in the fall of 2023. Survey participants characteristics: Age: 50–59, 10%; 60–69, 25%; 70–79, 43%; 80+, 22%. Gender: men 39%; women 61%. Race: white 95%; other 5%. 
Coming Soon

JOE and AML

Keep an eye out for upcoming announcements!

CANCER EXPERIENCE REGISTRY SURVEY
We are excited to join forces with Cancer Support Community to share their newly launched MDS Cancer Experience Registry (CER). The Cancer Experience Registry is a free and confidential online survey for anyone who has ever been diagnosed with cancer, and for caregivers of individuals with cancer, to share their cancer experience. The findings gathered from these surveys will illustrate the Cancer Support Community’s commitment to putting the voices of patients and caregivers at the center of the conversation about cancer. By taking the survey, you join thousands of others in helping to: influence health care policies, enhance cancer care, and improve support services. Join today and elevate your voice!

Use the QR code to take the survey!

CancerSupportCommunity.org/Registry

MDS JOE is brought to you by the MDS Foundation
The first global education and awareness initiative that provides patients and caregivers with the information, resources, and support they need to deal with AML.

Know AML has a dedicated and highly experienced global ambassador group who meet regularly to steer and guide the initiative. The ambassador group consists of patients and caregivers, patient advocates, healthcare professionals, and industry representatives. Their responsibility is to propose awareness initiatives, provide concepts for support and education resources, share their experiences and learnings from advocacy heritage, and endorse materials before circulation among the AML community.

AML World Awareness Day is the one day of the year that people from all around the world come together to help raise awareness of acute myeloid leukemia (AML) – a rare, aggressive cancer of the blood and bone marrow and the most common form of acute leukemia in adults.
MDS Foundation Patient and Caregiver Survey

The Results Are In...

The Myelodysplastic Syndromes Foundation (MDSF) has conducted a patient and caregiver survey from 2015 – 2023. Over the course of this time, a total of 597 participants completed the survey.

Who Took the Survey?

The demographics of the survey were as follows:

<table>
<thead>
<tr>
<th>Average patient age</th>
<th>Average caregiver age</th>
<th>Range for year of diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>69</td>
<td>61</td>
<td>1985 – 2022</td>
</tr>
</tbody>
</table>

An estimated 52.67% of the respondents reported having been seen at a MDS Center of Excellence. The four centers with the most survey respondents were as follows: Moffitt (17 participants), Fred Hutchinson (17 participants), Columbia (14 participants), and Stanford (11 participants). Although the majority are seen at Centers of Excellence, 71.57% receive treatment at a local hematology clinic; thus, demonstrating an ongoing partnership between the two. The survey revealed that the foundation is reaching people primarily in the Northeast and Southeast regions of the United States, with the least number of participants located in the Rocky Mountain region.

Given the rise of technology utilization in healthcare, questions were added to the survey to determine how the MDS patient and caregiver population has incorporated digital platforms into their care. Between 70 and 80% of those surveyed reported using a smartphone daily; 30–40% reported daily use of a tablet. Despite the popularity of handheld devices, 78.41% still preferred printed health information.

As respondents were allowed to select more than one modality for education delivery, it is important to note that 71.36% reported that they would prefer written material online. The takeaway is that patients are seeking health literature rather than visual or interactive venues. When asked where they go to for health information, the following were the top three contenders: the internet (between 250–300 respondents), the MDS Foundation (between 150–200 respondents), and healthcare professionals (between 150–200 respondents).

Participants were asked about clinical trials. An estimated 61.19% of respondents reported that they have considered participating in a clinical trial, while only 13.88% have been a trial participant. The majority of patients, 59.21%, reported that their provider had not discussed clinical trials with them and 60.62% stated that they receive information on MDS clinical trials from the MDS Foundation. The internet was another common source of trial knowledge; 12.6% of those surveyed reported finding data from internet searches.

What were the Results?

Participants were asked about clinical trials. An estimated 61.19% of respondents reported that they have considered participating in a clinical trial, while only 13.88% have been a trial participant. The majority of patients, 59.21%, reported that their provider had not discussed clinical trials with them and 60.62% stated that they receive information on MDS clinical trials from the MDS Foundation. The internet was another common source of trial knowledge; 12.6% of those surveyed reported finding data from internet searches.

Given the rise of technology utilization in healthcare, questions were added to the survey to determine how the MDS patient and caregiver population has incorporated digital platforms into their care. Between 70 and 80% of those surveyed reported using a smartphone daily; 30–40% reported daily use of a tablet. Despite the popularity of handheld devices, 78.41% still preferred printed health information.

As respondents were allowed to select more than one modality for education delivery, it is important to note that 71.36% reported that they would prefer written material online. The takeaway is that patients are seeking health literature rather than visual or interactive venues. When asked where they go to for health information, the following were the top three contenders: the internet (between 250–300 respondents), the MDS Foundation (between 150–200 respondents), and healthcare professionals (between 150–200 respondents).

The most important questions of the survey resolved around what patients and caregivers have identified as the gaps in care. Of note, only 6.5% of respondents were satisfied with the currently available resources. Per those surveyed, the top three areas of need identified were the following:

**COMMUNITY**
- Emotional Support (23.2%)
  - Caregiver resources
  - Generalized emotional support
  - More support groups
  - Other patients’ stories/ experiences
  - Information on impact on younger patients

**QUALITY**
- Better format & delivery (21.8%)
  - New printed information
  - Less medical jargon
  - More patient forums and events
  - Increase in internet-based resources
  - Update of the MDSF website
  - Information provided in more languages

**AWARENESS**
- Advances in MDS (16.7%)
  - International and global advances in treatment
  - New updates in the MDS space
  - Homeopathic therapies
  - Clinical trials
  - Access to research articles
  - Help identifying reputable sources
  - MDSF news
MDS Foundation Patient and Caregiver Survey

As treatment for MDS becomes a priority, it is important to remember that patients have other co-morbidities and healthcare needs which must be met outside of the realm of hematology. It was encouraging to see that 69.90% of respondents had seen their primary care physician within the past three months. 78.31% reported seeing other medical specialists on a routine basis. The 368 participants who answered this question identified a total of 758 medical specialists; this equates to ~2.05 sub-specialties per person. The top three medical disciplines noted by MDS patients in the survey were cardiovascular (35.8%), urin ary/reproductive (33.9%), and integumentary (26.6%). Polypharmacy is a concern for this medically complex group. When asked how many prescription medications are being taken, the average was 4 per person. When factoring in over-the-counter medications, the 403 patients who answered this question identified the following as the top three categories of non-prescription medications taken: vitamins (68.2% of those surveyed), medications for heart health (24% of those surveyed), and pain management (17.6% of those surveyed).

It became apparent that MDS patients are proactive in their healthcare. 87.66% reported attending classes aimed at health and wellness. 77.45% reported following a special diet with the majority adhering to a low carbohydrate/diabetic diet (between 30 – 35 patients). Despite the focus on nutrition, adequate caloric intake remains a challenge with 51.88% of patients reporting a poor appetite.

Diets Followed

A group of questions was focused on quality of life and symptom burden of the disease. Fatigue is a real problem for MDS patients with 28.57% waking up tired each morning and 48.79% feeling tired at the end of the day. Approximately 25% reported having trouble starting things due to fatigue; an equal number reported difficulty ending projects for the same reason. 59.56% reported needing medication to assist with insomnia. The end result is that 35.46% of those surveyed reported limiting activities due to fatigue.

The psychological impact of MDS can be life altering. The majority of patients (55.46%) reported feeling isolated and alone. 33.56% experience anxiety. 37.03% experience depression, and 35.19% experience uncertainty; this does not take into account those who are not comfortable with reporting the mental health impact of the disease. 26.06% of those surveyed reported relying on family and friends to complete activities of daily living. Despite the challenges, it is encouraging to hear that 45.43% of those surveyed remain hopeful. Those impacted by MDS prove to be consistently resilient.

Where do we go from Here?

The MDS Foundation is in the process of using these survey results to develop a targeted outreach approach. The focus is on emotional support. Support group information, to include a leadership toolkit, is now being promoted at patient forum events. The Director of Patient Care is making an effort to clean up support group information, join support group calls, and facilitate the development of new groups. In addition, the MDS Foundation is updating and promoting Colloquy, a social media platform created for and dedicated to those impacted by MDS.

Improving information delivery is also a top priority. Stay tuned for reconstruction updates for the foundation website. The MDS Foundation has partnered with IPNY to improve marketing and communication efforts. MDS Foundation supported publications including the Building Blocks of Hope and Guide to Assistance Programs are being updated and will be ready for distribution soon; part of this update will involve translations into other languages to include Japanese.

Given the interest in clinical trials, the foundation is working to distribute accurate, easy to navigate information on MDS clinical trials to patients and providers. The MDS Foundation has partnered with SparkCures to develop a unique platform which allows patients and providers to search for clinical trials based on individual disease characteristics and location. Patients and providers can create accounts, set up phone appointments with SparkCures and MDSF staff, and filter by commonly used trial criteria. Filters include center, subtype, treatment history, risk level, drug classification, trial phase, trial type, organ function, and more. As new drugs are approved, the foundation staff are dedicated to the distribution of press releases. In addition, the MDS Foundation has close partnerships with pharmaceutical companies and plans to continue serving as advisors on the patient experience. One such example of this was the partnership of Bristol Myers Squibb and the MDS Foundation for a presentation at the Reblozy Relaunch in September 2023 after the drug was approved as a front-line therapy.

Partnerships are important to nonprofit organizations. The MDS Foundation plans to strengthen its relationship with the Centers of Excellence by creating a culture of community. A referral network is being developed and a meeting structure is being established. A one-page flyer for distribution at the centers was created this year as an introduction to the foundation for new patients. The MDS Foundation will also be hosting its first meet-and-greet event for Centers of Excellence representatives at the American Society of Hematology meeting in 2024. As communication among the centers increases, so will patient satisfaction.

In an effort to remain patient focused, the MDS Foundation is now working to update the survey with plans to review the data on a yearly basis. The survey will be re-opened in the very near future. The foundation also plans to release quarterly patient and caregiver interaction metrics which will give details on the number of patients impacted.
PleXus Communications is pleased to partner with the MDS Foundation on the Community Hematology/Oncology Forums

Optimizing Therapy for Low-risk Myelodysplastic Syndromes in Community Practice

Email info@plexuscomm.com for additional info and/or to request a program

Coming in early 2024

This webinar is held in partnership with the MDS Foundation

Optimizing Therapy for Low-risk Myelodysplastic Syndromes

Patient/Caregiver Live Webinar

Email: mdswebinar@plexuscomm.com to receive webinar link

This activity is supported by an educational grant from Bristol Myers Squibb.

Request a free live (in-person or webinar) expert-led CME/CE-accredited presentation for your hem/onc department.

Casey O’Connell, MD
Associate Professor of Clinical Medicine, Lawrence and Janice Kelly Chair in Hematology, Medical Director for Anticoagulation Services for LAC+USC, Director, Gehr Cures: Myeloid Malignancy Program of USC, Keck School of Medicine of USC

This activity is supported by an educational grant from Bristol Myers Squibb.
Learn More About Our Industry Partners

Notable: Understanding and Seeking Answers

Despite comprehensive research efforts around the globe to understand the underlying causes and therapeutic targets of Myelodysplastic Syndromes (MDS), there are currently no cures outside of transplant and no real confirmatory etiology (cause). Myelodysplastic Syndromes refer to a group of disorders in which the bone marrow produces too few mature and/or functioning red blood cells, white blood cells or platelets. It begins with a change to a normal stem cell in the bone marrow. The overall incidence of MDS in the United States is estimated at close to four cases per 100,000 people, with as many as 20,000 to 30,000 people diagnosed annually. There may be 60,000 to 170,000 people suffering with MDS in the US alone.

A central part of understanding MDS is really understanding and seeking answers for patients and through this work, creating the scientific insights for finding the medicine that delivers the greatest and most durable medical impact for the patient. Patients have shared tough parts of their journeys:

“...the years rolled by the appointments got closer together as my illness progressed. I’ve had sepsis around 14 times. I’ve had serious line infections from having a Hickman line inserted into my chest which would sit just above my heart. Last year I had 2 types of flu and have had flu every year since I had my transplant as well as a few times before. I’ve had NG and NJ tubes and still have a PEG I inserted in my tummy due to long periods of not being able to eat.” [K.B., MDS patient]

“Another biopsy confirmed Taylor’s marrow was still empty and along with the tri-lineal cytopenia confirmed the situation was still dire and maybe progressing. This biopsy also revealed some cytogenic anomalies for the first time (del 7q). It was stem cell transplant time for Taylor. The diagnosis for Taylor was ultimately hypoplastic MDS.” [T.B., MDS Patient]

“I had to wait for the disease to decide its course before we could look at treatment options. We found out that the medication that would usually be used, would not work for me... I was nervous but I had seen three different Hematologists / Oncologists, so I knew I had to keep the faith. I kept focusing on one sequence, del (5q), as my white counts and blasts continued to rise.” [S.N., MDS Patient]

“We at Notable see many common concerns among patients and while each patient’s journey is different, many similar obstacles and challenges have compelled us to seek improved, faster answers, especially to one of the most important questions of patients: “Doctor, will this therapy you’re recommending actually work for me?”

We believe: “EACH PATIENT IS NOTABLE AND CAN BENEFIT FROM A PREDICTIVE PRECISION MEDICINE THAT WORKS FOR THEM”. Following our recent merger and public launch on the NASDAQ, we are focusing the resources of the integrated company on advancing and accelerating medical progress for patients with MDS, AML, and other hematological diseases.

Notable’s PPMP, our proprietary Predictive Precision Medicines Platform, aims to predict, before treatment, whether a patient will clinically respond to their treatment (or not), is at the heart of what patients want to know and what their clinicians want to determine. We’re focused on bringing the clinical community improved, predictable outcomes – while enabling the acceleration of medical decisions and simplifying medical practice.

Predicting a patient’s clinical response can match treatments with the patients who are most likely to respond, potentially ensuring medical benefit for them and protecting the other patients, who traditionally would have been treated but not responded, from losing time, experiencing toxicity, and achieving better outcomes.

Beyond improving patient outcomes, predicting treatment response advances the development of novel medicines. Selectively enrolling predicted responders into clinical trials should make trials more likely to succeed and should result in trials that are smaller, faster, and less costly. Bringing medicines to patients faster and more predictably benefits all concerned.

Enabled by the combined resources of the two companies, we’re expanding our recent strong results of four clinical validation studies in partnership with Stanford University, MD Anderson Cancer Center, Washington University, and Texas Children’s Hospital.

Our team at Notable has built a clinical-stage platform therapeutics company that is developing predictive precision medicines for patients with cancer. With the PPMP, our platform bio-simulates a cancer treatment and predicts whether or not a patient is likely to respond to that specific therapeutic choice. We employ the industry’s largest cancer response database without a reliance on genomics and apply machine learning and AI. Our PPMP enables the identification and selection of clinically responsive patients prior to their treatment and thereby potentially enables fast-track clinical development in this patient population. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in precision medicine and revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient and cancer by cancer.

Notable is proud to be a National Gold Sponsor of “MOVE for MDS 2023”. We are headquartered in Foster City, California. Learn more at www.notablelabs.com and follow us @notablelabs.
Patients are our Priority.

At Servier Pharmaceuticals our deep commitment to our patients is fundamental to our unique culture — it is a priority in everything we do.

ServierONE is your all-in-one resource for help with the cost of treatment, determining insurance coverage, one-on-one support, and access to additional resources and educational tools.

---

CLINICAL TRIALS
NOW ENROLLING

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
- APG-115 is a potent, orally bioavailable MDM2 inhibitor which restores p53 expression and activates p53-mediated cell death in tumor cells.
- Recruiting patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high-risk myelodysplastic syndrome (MDS).
- For more information, visit https://www.clinicaltrials.gov/ and search: NCT04358393

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
- APG-2575 is an orally active, highly selective small molecule antagonist of Bcl-2 leading to induction of tumor cell apoptosis and eventual death.
- Recruiting patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML), mixed phenotype acute leukemia (MPAL), chronic myelomonocytic leukemia (CMML), or high-risk myelodysplastic syndrome (MDS).
- For more information, visit https://www.clinicaltrials.gov/ and search: NCT04964518

For additional questions, email: clinical-trials@ascentage.com
The SYROS SELECT trials are investigating tamibarotene, a selective and potent oral RARα agonist, in certain patients with HR-MDS and AML.

AML, acute myeloid leukemia; HR-MDS, higher-risk myelodysplastic syndrome; RARα, retinoic acid receptor alpha.

Tamibarotene is an investigational agent and is not approved for use in any indication in the U.S. or Europe.

© 2022 Syros Pharmaceuticals, Inc. All Rights Reserved.

Helping patients obtain access to Taiho Oncology medicines

Learn about our hematology product at TaihoOncology.com/US/
**NOW ENROLLING**

**LEUKEMIA TRIAL**

**TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome**

**BRIEF SUMMARY:**
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS).

- FLT3m positive and who have received ≤2 lines of prior treatment
- Spliceosome mutation of SF3B1 or U2AF1 and ≤2 lines of prior treatment

**PHASE 1/2A STUDY DESIGN:**

1. **PHASE 1A**
   - COMPLETED
   - 28-DAY CYCLE

2. **PHASE 2A**
   - Recommended Phase 2 Dose
     - 300 mg BID
   - OPEN
   - 28-DAY CYCLE

**Contact your doctor to discuss participating in this clinical trial. For more information about emavusertib visit ClinicalTrials.gov and search NCT04278768.**

**WE ARE**
working relentlessly to develop innovative and differentiated therapeutics that improve the lives of cancer patients
BRIEF SUMMARY OF PHASE 2A

The Phase 2a Dose Expansion will be in 3 Cohorts of patients:
1. R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor;
2. R/R AML with spliceosome mutations of SF3B1 or U2AF1; and
3. R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1.
All patients above will have had ≤ 2 lines of prior systemic anticancer treatment.

TREATMENT CYCLE
Emavusertib tablets are administered twice daily by mouth. Each treatment cycle is 28 days in length and repeated in the absence of toxicity. Patients who tolerate emavusertib may continue to receive emavusertib until progression of disease, intolerable toxicity, lack of clinical benefit, withdrawal from the trial, or study termination.

KEY ELIGIBILITY CRITERIA

INCLUSION CRITERIA:
• Males and females ≥18 years of age
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1
• Cytomorphology based confirmed diagnosis of MDS or AML (as per WHO 2016 classification) with the following characteristics.
  Phase 2a Dose Expansion (Monotherapy)
  Patients with:
  • R/R AML with FLT3 mutations who have been previously treated with a FLT3 inhibitor
  • R/R AML with spliceosome mutations of SF3B1 or U2AF1
  • R/R hrMDS (IPSS-R score > 3.5) with spliceosome mutations of SF3B1 or U2AF1
  • Number of pretreatments: 1 or 2
  • Acceptable organ function at screening
  • Negative serum pregnancy test in women of childbearing potential
  • Women of childbearing potential and men who partner with a woman of childbearing potential must agree to use highly effective contraceptive methods for the duration of the study and for 90 days after the last dose of emavusertib
  • Able to undergo serial bone marrow sampling and peripheral blood sampling

EXCLUSION CRITERIA:
• Diagnosed with acute promyelocytic leukemia (APL, M3)
• Has known active central nervous system (CNS) leukemia
• Allogeneic hematopoietic stem cell transplant (Allo-HSCT) within 60 days of the first dose of emavusertib, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to start of emavusertib
• Chronic myeloid leukemia (CML)
• Any prior systemic anti-cancer treatment such as chemotherapy, immunomodulatory drug therapy, etc., received within 3 weeks (or 5 half-lives) prior to start of emavusertib. Localized radiation or surgical resection of skin cancers allowed.
• Use of any investigational agent within 3 weeks or 5 half-lives, whichever is shorter, prior to start of emavusertib
• Presence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia that has not resolved to Grade ≤ 1 within 7 days prior to start of emavusertib; presence of any acute or chronic non-hematological toxicity ≥ Grade 3 at Screening, or prior to start of emavusertib must resolve to ≤ Grade 2.
• Pregnant or lactating

POSSIBLE RISKS
All study drugs have the potential to cause side effects. Before deciding to enroll in this study, all patients should carefully consider the potential benefits and risks with the healthcare provider. Study doctors will review the risks with every patient and will closely monitor all enrolled participants for side effects throughout the study.
Meeting Highlights and Announcements

POST CONGRESS REPORT:

The 17th International Congress on Myelodysplastic Syndromes

MARSEILLE, FRANCE • 3-6 MAY 2023

Top 10 Countries Attending (n):

- United States (108)
- France (10)
- Germany (39)
- United Kingdom (34)
- Spain (33)
- Canada (23)
- Italy (38)
- Greece (14)
- Sweden (1)
- Czech Republic (13)

PARTICIPANT STATISTICS

516 delegates from 39 countries spanning the globe participated.

Participants by Region (n):

- Western Europe (298)
- North America (131)
- East Asia & Pacific (34)
- Eastern Europe (22)
- Central & South America (16)
- Middle East (13)
- Central Asia (1)
- Africa & Atlantic (1)

Participants by Age (%):

- 18–30 years old (10%)
- 30–40 years old (22%)
- 40–50 years old (32%)
- 50–60 years old (17%)
- 60+ years old (19%)
Participants by Professional Role (%):
- Clinical Practitioner (33%)
- Clinician Researcher (24%)
- Basic Science Researcher (12%)
- Other (8%)
- Student (8%)
- Industry/Corporate Professional (7%)
- Resident/Research Fellow (4%)
- Nurse/Healthcare Practitioner (4%)

Participants by Professional Interest (%):
- Hematology (73%)
- Other (8%)
- Oncology (7%)
- Medical Genetics and Genomics (5%)
- Biochemistry/Molecular Biology (4%)
- Pathology (2%)
- Pediatrics (1%)
- Clinical Pharmacology (0%)

Participants by Workplace (%):
- Hospital (51%)
- Laboratory (12%)
- University Hospital (10%)
- Industry (9%)
- Research Institute (6%)
- Comprehensive Care Clinic (4%)
- University (4%)
- Other (4%)
- Government Agency (0%)
- Private Practice (0%)

SCIENTIFIC PROGRAM

Number of Sessions per Session type:

- **13** Plenary Sessions
- **6** Meet the Expert Sessions
- **3** Workshops
- **2** Nurse Program Sessions
- **1** Young Investigators Award Session

In total the congress had 67 Invited Speakers and Moderators from 10 countries, with some appearing in several sessions.

Canada • France • Germany • Israel • Italy • Japan • Netherlands • Spain • Sweden • USA

ABSTRACT SUBMISSION

- **194** Total Abstracts Received

United States • Spain • Brazil • Germany • Italy • France • Greece • Canada • United Kingdom • China • Czech Republic • Japan • Sweden • Argentina • Israel • Australia • South Korea • Taiwan • Uruguay • Austria • Uzbekistan • Algeria • Armenia • Chile • India • Jordan • Mexico • Qatar • Romania • Singapore

INDUSTRY SYMPOSIUM

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>SYMPOSIUM TYPE</th>
<th>ATTENDANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>Plenary</td>
<td>130</td>
</tr>
<tr>
<td>ASTEX</td>
<td>Pipeline</td>
<td>85</td>
</tr>
<tr>
<td>BMS</td>
<td>Plenary</td>
<td>110</td>
</tr>
<tr>
<td>KEROS</td>
<td>Pipeline</td>
<td>85</td>
</tr>
</tbody>
</table>

SPONSORSHIP & EXHIBITION

- **9** sponsors

Diamond: Bristol Myers Squibb
Gold: Abbvie, Gilead
Silver: Astex, Keros, Novartis
General Supporter: Alexion
Educational Supporters: Bristol Myers Squibb, Syros, Taiho Oncology
Meeting Highlights and Announcements

This is a Friday Satellite Symposium preceding The 65th American Society of Hematology Annual Meeting

Breakfast Symposium
Myelodysplastic Syndromes 2023: What’s New

Friday, December 8, 2023 • 7:00-10:00am

This activity is jointly-provided by The Myelodysplastic Syndromes Foundation, Inc. and AKH Inc., Advancing Knowledge in Healthcare. This activity is supported by an educational grant from Astex, BMS, Geron, Notable, and Taiho.

Welcome to the latest edition of touchREVIEWS in Oncology & Haematology! This issue features some of the recent key developments in oncological and haematological disease, including expert interviews, editorials and review articles exploring the latest in lung cancer, pediatric oncology, breast cancer, colorectal cancer, esophageal squamous cell carcinoma, biliary tract cancer, urothelial carcinoma, squamous cell anal carcinoma, cold agglutinin disease and multiple myeloma.

We would like to take this opportunity to thank all who contributed towards this edition, in particular our authors, Editor-in-Chief, editorial board members and partners.

We are now welcoming submissions to our 2023/2024 editions. If you’re interested in submitting an article, please get in touch!

Enjoy and happy reading!

MDS Foundation Leadership

Board of Directors

Pierre Fenaux, MD
Hôpital St Louis, Université de Paris

Peter L. Greenberg, MD
Stanford University School of Medicine

Sandra E. Kurtin, PhD, ANP-C, AOCN
The University of Arizona Cancer Center

Luca Malcovati, MD
University of Pavia Fondazione IRCCS Policlinico San Matteo

Stephen D. Nimer, MD, Chair
Sylvester Comprehensive Cancer Center

Michael R. Savona, MD
Vanderbilt University School of Medicine

Officers

Stephen D. Nimer, MD, Chair
Tracey Iraca, Executive Director
Sandra E. Kurtin, PhD, ANP-C, AOCN, Treasurer
Lea Harrison, Secretary

MEMBERS EMERITUS

John M. Bennett, MD
University of Rochester Medical Center

Eva Hellström-Lindberg, MD, PhD
Karolinska Institute at Karolinska University Hospital Huddinge

Charlotte M. Niemeyer, MD
University Children’s Hospital

Franz Schmatzli, MD
Innsbruck, Austria

Development Board

Deborah Peirce, Chair
Talent/Leadership and Organizational Development Executive, MDS Caregiver

Stuart Goldberg, MD
MDS Specialist

Jennifer Keam, MD, MPH
MDS Caregiver

Julia McGuire, Advisor
Executive Vice President, Campbell & Company
Madeleine’s Mom, MDS Patient

Robert Smith, CPA, CGMA
MDS Certified Public Accountant

Lindsay Wilde, MD
MDS Specialist

Jim Williams
MDS Survivor and Health Care Entrepreneur

International Nurse Leadership Board

Erik Aerts, RN, President HNHCP
Zürich, Switzerland

Angelika Bitter, Dresden, Germany

Mariela Andrea Blanco, RN
Buenos Aires, Argentina

Claudia Boglione, RN, Florence, Italy

Jordan Hwang Chung Cheng, RN, MN, ADV. Dip. (Oncology Nursing)
Singapore

Nicole Crisp, RN, BScN, MN, NP-adult
Edmonton, Alberta, Canada

Erin Demakos, RN, CCRN
New York, New York, United States

Rebecca Dring, RN
Masters of Advanced Nursing Practice
Melbourne, Australia

Lenn Fechter, RN
Stanford, California, United States

Janet Hayden, RN, BSc (hons), MPH
London, United Kingdom

Amelia Hodson, AG-ACNP
Charlottesville, Virginia, United States

Miki Iizuka, RN
Tokyo, Japan

Jacqueline Jagger, BA, RN, MN
Gosford, Australia

Natasha L. Johnson, MS, APRN, AOCNP
Tampa, Florida, United States

Sandra E. Kurtin, PhD, ANP-C, AOCN
Tucson, Arizona, United States

Petra Lindros Kolqvist, RN
Goteborg, Sweden

Sarah Jayne Lipcott, PhD, MSc, BN(Hons), Onc. Cert., Milan, Italy

Ashley Moncrief, RN, BSN
Nashville, Tennessee, United States

Cindy Murray, RN, MN, NP-adult
Toronto, Ontario, Canada

Geke Ong, RN, London, United Kingdom

Phyllis Paterson, RN, RSCN, Dip. Onc.
Cambridge, United Kingdom

Samantha Soggee, RN, MN
Geelong, Victoria, Australia

Amber Thomassen, AGPC NP-BC, AOCNP
Miami, Florida, United States

Sara M. Tinsley, PhD, APRN, AOCN
Tampa, Florida, United States

Catherine Vassili, NP, MN
Victoria, Australia
MDS Risk Assessment Calculators

The IWG-PM under the aegis of the MDS Foundation, Inc has developed two prognostic tools, the IPSS-M and IPSS-R Calculators, to determine a patient’s risk of progressing to Acute Myeloid Leukemia (AML).

**IPSS-M CALCULATOR**

The IPSS-M is the newest MDS prognosis calculator that combines genomic profiling with hematologic and cytogenetic parameters, improving the risk stratification of patients with MDS.

This is a valuable tool for clinical decision-making, offering the prospect of tailoring diagnosis and therapeutic interventions to each patient’s molecular profile.

https://www.mds-foundation.org/mds-iwg-pm/

**IPSS-R CALCULATOR**

The IPSS-R is the current MDS prognosis calculator that combines hematologic and cytogenetic parameters to determine an MDS patient’s risk stratification. This calculator tool includes clinical features of marrow blasts, cytogenetics, depth of cytopenias and age as well as the additive differentiate features for patient survival of performance status, serum ferritin, LDH, beta-2 micro globulin and marrow fibrosis.

https://www.mds-foundation.org/advanced-calculator

DOWNLOAD IPSS-M CALCULATOR APP

DOWNLOAD IPSS-R CALCULATOR APP
MDS Centers of Excellence

Our MDS Centers of Excellence are institutions that meet the highest standards for diagnosis, treatment and patient care. These centers help patients seeking first or second opinions and/or additional treatment options from experts in MDS. We currently have 77 Centers in the United States and 121 Centers in countries around the world.

https://www.mds-foundation.org/mds-centers-of-excellence

BENEFITS OF MEMBERSHIP:

- MDSF CoEs form the referral base for the patients who contact the Foundation daily.
- MDSF CoEs are proudly recognized on the Foundation website, within our printed newsletters, and through our various social media platforms.
- MDSF CoEs are offered discounted registration rates at MDS Foundation meetings and a 60% annual subscription discount to Leukemia Research.
- MDSF CoEs have full access to MDSF educational resources for distribution to your patients.
- In addition, along with your $500 CoE renewal payment, your annual MDSF Professional Membership dues are waived.
- MDSF Professional Members are also listed, by name, on our website and in our printed newsletters.
- The work of your institution can be shared with our patient and professional contacts via our website and/or our social media channels.

We can spread the word of your clinical trials, research projects, etc.

Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence?

TO BE RECOGNIZED AS A CENTER OF EXCELLENCE, AN INSTITUTION MUST HAVE THE FOLLOWING:

- Available cytogenetics and/or molecular genetics
- Recognized morphologic expertise in MDS
- An established university (or equivalent) program
- Ongoing research, including Institutional Review Board–approved clinical trials
- Documentation of peer-reviewed publications in the field

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

<table>
<thead>
<tr>
<th>UNITED STATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALABAMA</td>
</tr>
<tr>
<td>University of Alabama at Birmingham</td>
</tr>
<tr>
<td>Birmingham Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Birmingham, Alabama</td>
</tr>
<tr>
<td>Kimo Bachiaashvili, MD</td>
</tr>
<tr>
<td>ARIZONA</td>
</tr>
<tr>
<td>Mayo Clinic Hospital</td>
</tr>
<tr>
<td>Phoenix, Arizona</td>
</tr>
<tr>
<td>Cecilia Arana Yi, MD/James Slack, MD</td>
</tr>
<tr>
<td>The University of Arizona Cancer Center</td>
</tr>
<tr>
<td>Tucson, Arizona</td>
</tr>
<tr>
<td>Ravi Krishnadasan, MD, FACP/Jeffrey Pu, MD</td>
</tr>
<tr>
<td>CALIFORNIA</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>UCLA School of Medicine</td>
</tr>
<tr>
<td>Los Angeles, California</td>
</tr>
<tr>
<td>H. Phillip Koeffler, MD</td>
</tr>
<tr>
<td>City of Hope National Medical Center</td>
</tr>
<tr>
<td>Duarte, California</td>
</tr>
<tr>
<td>Peter Curtin, MD/Stephen J. Forman, MD</td>
</tr>
<tr>
<td>Moores Cancer Center – UC San Diego Health</td>
</tr>
<tr>
<td>San Diego, California</td>
</tr>
<tr>
<td>Rafael Bejar, MD, PhD/Tiffany N. Tanaka, MD</td>
</tr>
<tr>
<td>Stanford University Medical Center</td>
</tr>
<tr>
<td>Stanford, California</td>
</tr>
<tr>
<td>Peter L. Greenberg, MD</td>
</tr>
<tr>
<td>UCLA Health Hematologic Malignancies and Stem Cell Transplant Program</td>
</tr>
<tr>
<td>Los Angeles, California</td>
</tr>
<tr>
<td>Gary J. Schiller, MD</td>
</tr>
<tr>
<td>University of Southern California Keck School of Medicine</td>
</tr>
<tr>
<td>Los Angeles, California</td>
</tr>
<tr>
<td>Casey L. O’Connell, MD</td>
</tr>
<tr>
<td>COLORADO</td>
</tr>
<tr>
<td>University of Colorado School of Medicine</td>
</tr>
<tr>
<td>University of Colorado Cancer Center</td>
</tr>
<tr>
<td>Aurora, Colorado</td>
</tr>
<tr>
<td>Daniel Aaron Poliyea, MD, MS</td>
</tr>
<tr>
<td>Maria Amaya, MD, PhD – Practice Location: Rocky Mountain Regional VA Christine McMahon, MD – Practice Location: UCHealth Blood Disorders and Cell Therapies Center – Anschutz Medical Campus</td>
</tr>
<tr>
<td>CONNECTICUT</td>
</tr>
<tr>
<td>Yale Cancer Center/Smilow Cancer Hospital</td>
</tr>
<tr>
<td>Yale University School of Medicine</td>
</tr>
<tr>
<td>New Haven, Connecticut</td>
</tr>
<tr>
<td>Amer Zeidan, MD</td>
</tr>
<tr>
<td>FLO RIDA</td>
</tr>
<tr>
<td>Blood and Marrow Transplant Center</td>
</tr>
<tr>
<td>Advent Health Cancer Institute</td>
</tr>
<tr>
<td>Orlando, Florida</td>
</tr>
<tr>
<td>Juan Carlos Varela, MD, PhD</td>
</tr>
<tr>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Jacksonville, Florida</td>
</tr>
<tr>
<td>James M. Foran, MD</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>Tampa, Florida</td>
</tr>
<tr>
<td>Rami Komrokji, MD/Alison R. Walker, MD</td>
</tr>
<tr>
<td>Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine</td>
</tr>
<tr>
<td>Miami, Florida</td>
</tr>
<tr>
<td>Stephen D. Nimer, MD/Mikkael Sekeres, MD, MS</td>
</tr>
<tr>
<td>University of Florida Shands Hospital</td>
</tr>
<tr>
<td>Gainesville, Florida</td>
</tr>
<tr>
<td>Zeina Al-Mansour, MD</td>
</tr>
</tbody>
</table>
MDS Foundation Centers of Excellence

GEORGIA
Emory Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Amelia Langston, MD
Nikolaos Papadantonakis, MD, PhD, MSc
The Blood and Marrow Transplant Program at Northside Hospital
Atlanta, Georgia
Asad Bashey, MD

ILLINOIS
Loyola University Chicago
Cardinal Bernardin Cancer Center
Maywood, Illinois
Stephanie B. Tsai, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Feinberg School of Medicine
Chicago, Illinois
Jamile Shammo, MD
Rush University Medical Center
Chicago, Illinois
Melissa L. Larson, MD
University of Chicago Medical Center
Chicago, Illinois
Richard A. Larson, MD

INDIANA
Indiana University Simon Cancer Center
Indianapolis, Indiana
Larry Cripe, MD/Hamid Sayar, MD, MS

IOWA
The University of Iowa Hospitals and Clinics, Holden Cancer Center
Iowa City, Iowa
Grek Sutamtewagul, MD

KANSAS
The University of Kansas Cancer Center
Westwood, Kansas
Barry Skikne, MD

MARYLAND
Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy Elizabeth DeZem, MD
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Maria R. Baer, MD

MASSACHUSETTS
Dana- Farber/ Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts
Akiko Shimamura, MD, PhD
Dana- Farber Cancer Institute
Boston, Massachusetts
Richard M. Stone, MD
Benjamin Ebert, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Timothy Graubert, MD
Tufts Medical Center
Boston, Massachusetts
Andreas Klein, MD

MICHIGAN
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Jay Yang, MD
William Beaumont Hospital Cancer Center
Royal Oak, Michigan
Ishmael Jaiyesimi, DO

MINNESOTA
Mayo Clinic
Rochester, Minnesota
Aref Al-Kali, MD
Mark R. Litzow, MD
Mineral S. Patnaik, MBBS
University of Minnesota Medical Center, Fairview University of Minnesota Medical School
Minneapolis, Minnesota
Mark B. Juckett, MD

MISSOURI
Washington University School of Medicine
Siteman Cancer Center
St. Louis, Missouri
Matt Walter, MD
Meagan Jacoby, MD

NEBRASKA
University of Nebraska Medical Center
Omaha, Nebraska
Lori Maness, MD

NEW HAMPSHIRE
Dartmouth- Hitchcock Medical Center and Norris Cotton Cancer Center
Lebanon, New Hampshire
Kenneth R. Meehan, MD

NEW JERSEY
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
James McCloskey, MD
Rutgers Cancer Institute of New Jersey
Rutgers University Hematologic Malignancies and Stem Cell Transplant
New Brunswick, New Jersey
Dale G. Schaar, MD, PhD

NEW MEXICO
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Leslie Andritsos, MD/Ala Ebaid, MD

NEW YORK
Albert Einstein Cancer Center/ Albert Einstein College of Medicine of Yeshiva University
Bronx, New York
Aditiasha, MD/Amit Verma, MD
Columbia University Medical Center
New York, New York
Azra Raza, MD
Memorial Sloan- Kettering Cancer Center
New York, New York
Aaron D. Goldberg, MD, PhD
Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell,
Monter Cancer Center
Lake Success, New York
Steven L. Allen, MD
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Maher Abdul Hay, MD
Icahn School of Medicine at Mount Sinai
New York, New York
Lewis R. Silverman, MD
New York Medical College/ Westchester Medical Center,
Zalmen A. Arlin Cancer Center
Valhalla, New York
Karen Seiter, MD
Roswell Park Cancer Center
Buffalo, New York
Elizabeth Griffiths, MD
James E. Thompson, MD
University of Rochester Medical Center
Rochester, New York
Jane L. Liesveld, MD
<table>
<thead>
<tr>
<th>State</th>
<th>Institution</th>
<th>City, State</th>
<th>loafers, MD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MDS Foundation Centers of Excellence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weill Medical College of Cornell</td>
<td>New York, New York</td>
<td>Gail J. Roboz, MD</td>
</tr>
<tr>
<td><strong>NORTH CAROLINA</strong></td>
<td>Atrium Health Levine Cancer Center</td>
<td>Charlotte, North Carolina</td>
<td>Srinivasa R. Sankkommu, MD, FACP, Michael Grunwald, MD</td>
</tr>
<tr>
<td></td>
<td>Duke University Medical Center</td>
<td>Durham, North Carolina</td>
<td>Carlos M. deCastro, MD</td>
</tr>
<tr>
<td></td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>Chapel Hill, North Carolina</td>
<td>Brandi Reeves, MD</td>
</tr>
<tr>
<td></td>
<td>Novant Health Cancer Institute</td>
<td>Charlotte, North Carolina</td>
<td>Patricia Kropf, MD</td>
</tr>
<tr>
<td></td>
<td>Wake Forest University School of Medicine Comprehensive Cancer Center</td>
<td>Winston-Salem, North Carolina</td>
<td>Bayard L. Powell, MD</td>
</tr>
<tr>
<td><strong>OHIO</strong></td>
<td>Cleveland Clinic Foundation, Taussig Cancer Center</td>
<td>Cleveland, Ohio</td>
<td>Jaroslaw Maciejewski, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Hoxworth Blood Center, George L. Strike</td>
<td>Cincinnati, Ohio</td>
<td>Emily Curran, MD</td>
</tr>
<tr>
<td></td>
<td>Bone Marrow Transplant Program</td>
<td>Columbus, Ohio</td>
<td>James S. Blachly, MD</td>
</tr>
<tr>
<td></td>
<td>The Ohio State Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute</td>
<td>Columbus, Ohio</td>
<td>Uma M. Borate, MD</td>
</tr>
<tr>
<td><strong>PENNSYLVANIA</strong></td>
<td>Allegheny Health Network Cancer Institute, Western Pennsylvania Hospital</td>
<td>Pittsburgh, Pennsylvania</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fox Chase- Temple University Hospital, Bone Marrow Transplant Program</td>
<td>Philadelphia, Pennsylvania</td>
<td>Henry Fung, MD, FACP, FRCPE, Rashmi Khanal, MD, Michael Styler, MD Asya Varshavy- Yanovsky, MD, PhD</td>
</tr>
<tr>
<td><strong>WASHINGTON</strong></td>
<td>UPMC Cancer Center</td>
<td>Pittsburgh, Pennsylvania</td>
<td>Ana stasios Raptis, MD, James M. Rossetti, DO</td>
</tr>
<tr>
<td></td>
<td>University of Pennsylvania Cancer Center</td>
<td>Philadelphia, Pennsylvania</td>
<td>Keith W. Pratz, MD</td>
</tr>
<tr>
<td></td>
<td>Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital</td>
<td>Philadelphia, Pennsylvania</td>
<td>Lindsay Wilde, MD</td>
</tr>
<tr>
<td><strong>TENNESSEE</strong></td>
<td>Vanderbilt University Medical Center</td>
<td>Nashville, Tennessee</td>
<td>Sanjay Mohan, MD, Michael R. Savona, MD</td>
</tr>
<tr>
<td><strong>TEXAS</strong></td>
<td>Texas Oncology – San Antonio</td>
<td>San Antonio, Texas</td>
<td>Roger M. Lyons, MD, FACP, John S. Renshaw, MD</td>
</tr>
<tr>
<td></td>
<td>Texas Oncology – Austin Midtown</td>
<td>Austin, Texas</td>
<td>Jason M. Melear, MD</td>
</tr>
<tr>
<td><strong>UTAH</strong></td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>Salt Lake City, Utah</td>
<td>Afaf Osman, MD</td>
</tr>
<tr>
<td><strong>VIRGINIA</strong></td>
<td>University of Virginia, Charlottesville, Virginia</td>
<td>Charlottesville, Virginia</td>
<td>Paul J. Shami, MD</td>
</tr>
<tr>
<td><strong>WASHINGTON</strong></td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Seattle, Washington</td>
<td>Joachim Deeg, MD, Bart L. Scott, MD</td>
</tr>
<tr>
<td><strong>WASHINGTON, DC</strong></td>
<td>Lombardi Comprehensive Cancer Center</td>
<td>Washington, D.C.</td>
<td>Catherine Broome, MD</td>
</tr>
<tr>
<td></td>
<td>George Washington University, VA Medical Center</td>
<td>Washington, D.C.</td>
<td>Anita Aggarwal, DO</td>
</tr>
<tr>
<td><strong>WISCONSIN</strong></td>
<td>Medical College of Wisconsin, Hematologic Malignancies Program</td>
<td>Milwaukee, Wisconsin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin, Madison Medical School</td>
<td>Madison, Wisconsin</td>
<td>Ryan Mattison, MD</td>
</tr>
<tr>
<td><strong>ARGENTINA</strong></td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
<td>Marcelo lastrebrner, MD</td>
</tr>
<tr>
<td><strong>ARMENIA</strong></td>
<td>Blood Disorders Center of Armenia, Hematology Center after R. Yeolyan</td>
<td>Yerevan, Armenia</td>
<td>Anna Sevoyan, MD</td>
</tr>
<tr>
<td><strong>AUSTRALIA</strong></td>
<td>Cabri ne Haematology &amp; Oncology Centre</td>
<td>Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monash Health Monash University</td>
<td>Clayton, Victoria, Australia</td>
<td>Jake Shortt, BMedSc, MBChB, FRACP, FRCPA, PhD</td>
</tr>
<tr>
<td></td>
<td>Peter MacCallum Cancer Institute, University of Melbourne</td>
<td>East Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Royal Hobart Hospital</td>
<td>Tasmania, Australia</td>
<td>Rosemary Harrup, MD</td>
</tr>
<tr>
<td></td>
<td>The Royal Melbourne Hospital</td>
<td>Parkville, Victoria, Australia</td>
<td></td>
</tr>
<tr>
<td><strong>INTERNATIONAL</strong></td>
<td>Geoff rge University Hospital, Lombardi Comprehensive Cancer Center</td>
<td>Washington, D.C.</td>
<td>Catherine Broome, MD</td>
</tr>
<tr>
<td></td>
<td>George Washington University, VA Medical Center</td>
<td>Washington, D.C.</td>
<td>Anita Aggarwal, DO</td>
</tr>
<tr>
<td></td>
<td>Medical College of Wisconsin, Hematologic Malignancies Program</td>
<td>Milwaukee, Wisconsin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin, Madison Medical School</td>
<td>Madison, Wisconsin</td>
<td>Ryan Mattison, MD</td>
</tr>
<tr>
<td><strong>ARGENTINA</strong></td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
<td>Marcelo lastrebrner, MD</td>
</tr>
<tr>
<td><strong>ARMENIA</strong></td>
<td>Blood Disorders Center of Armenia, Hematology Center after R. Yeolyan</td>
<td>Yerevan, Armenia</td>
<td>Anna Sevoyan, MD</td>
</tr>
<tr>
<td><strong>AUSTRALIA</strong></td>
<td>Cabri ne Haematology &amp; Oncology Centre</td>
<td>Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monash Health Monash University</td>
<td>Clayton, Victoria, Australia</td>
<td>Jake Shortt, BMedSc, MBChB, FRACP, FRCPA, PhD</td>
</tr>
<tr>
<td></td>
<td>Peter MacCallum Cancer Institute, University of Melbourne</td>
<td>East Melbourne, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Royal Hobart Hospital</td>
<td>Tasmania, Australia</td>
<td>Rosemary Harrup, MD</td>
</tr>
<tr>
<td></td>
<td>The Royal Melbourne Hospital</td>
<td>Parkville, Victoria, Australia</td>
<td></td>
</tr>
</tbody>
</table>
MDS Foundation Centers of Excellence

AUSTRIA
Hanusch Hospital
Medical University of Vienna
Vienna, Austria
Michael Pfeilstöcker, MD
Medical University of Vienna
Vienna, Austria
Peter Valent, MD
University Hospital of Innsbruck
Innsbruck, Austria
Reinhard Stauder, MD

BELGIUM
AZ Sint-Jan AV
Brugge, Belgium
Dominik Selleslag, MD
University Hospital Leuven
Leuven, Belgium
Marielle Beckers, MD, PhD
Michel Delforge, MD, PhD

BRAZIL
AC Camargo Hospital–Cancer Center
São Paulo, Brazil
Luiz Fernando Lopes, MD, PhD
Hospital das clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Elvira D. Rodrigues Pereira Velloso, MD, PhD
Universidade Federal de Ceará
Ceará, Brazil
Silvia Maria M. Magalhães, MD, PhD
Universidade Federal de São Paulo
São Paulo, Brazil
Maria de Lourdes Chauffaille, MD, PhD
Hospital Israelita Albert Einstein
São Paulo, Brazil
Nelson Hamerschlag, MD, PhD
Elvira D. Rodrigues Pereira Velloso, MD, PhD

CANADA
Princess Margaret Hospital
Toronto, Ontario, Canada
Karen Yee, MD
Odette Cancer Centre
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
Karin Buckstein, MD, FRCP
Richard A. Wells, MD
St. Paul’s Hospital
Vancouver, British Columbia, Canada
Heather Leitch, MD, PhD

University of Toronto Hospital
for Sick Children
Toronto, Ontario, Canada
Yigal Dror, MD

CHINA
Guangdong General Hospital & Guangdong Academy of Medical Sciences
Guangzhou, China
Xin Du, MD, PhD
Institute of Hematology and Blood Diseases Hospital
Chinese Academy of Medical Sciences
Tianjin, China
Zhijian Xiao, MD
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Jiangsu Province, China
Suning Chen, MD, PhD
The First Affiliated Hospital of Zhejiang University
Zhejiang Province, China
Hongyan Tong, MD, PhD
The Sixth Hospital Affiliated to Shanghai Jiaotong University
Shanghai, China
Chunkang Chang, MD, PhD

CROATIA
Clinical Hospital Merkur
Zagreb, Croatia
Inga Mandac Ragulj, MD

CZECH REPUBLIC
Institute of Hematology & Blood Transfusion
Prague, Czech Republic
Jaroslav Cermák, MD, PhD

DENMARK
Odense University Hospital
The University of Southern Denmark
Odense, Denmark
Klas Raaschou-Jensen, MD
Claus Marcher, MD
Rigshospitalet National University Hospital
Copenhagen, Denmark
Kirsten Grønbæk, MD
Lars Kjeldsen, MD, PhD

FRANCE
Centre Henri Becquerel
Rouen University School of Medicine
Rouen, France
Aspasia Stamatooulas, MD
Centre Hospitalier Universitaire (CHU) de Angers Service des Maladies du Sang
Angers, France
Norbert Ifrah, MD
Centre Hospitalier Universitaire (CHU) de Grenoble
Grenoble, France
Jean-Yves Cahn, MD
Centre Hospitalier Universitaire (CHU) de Limoges Hôpital Dupuytren
Limoges, France
Pascal Turlure, MD
Centre Hospitalier Universitaire (CHU) de Nancy
Nancy, France
Agnés Guerci-Bresler, MD, PhD
Centre Hospitalier Universitaire (CHU) de Tours – Bretonneau
Tours, France
Emmanuel Gyan, MD, PhD
Hôpital Cochin/ University Paris V
Paris, France
Francois Dreyfus, MD
Hôpital Saint Louis/ University Paris VII
Paris, France
Pierre Fenaux, MD, PhD
Christine Chomienne, MD, PhD
Hôpital Saint- Vincent de Paul (Lille)
Lille, France
Pascal Laurent, MD
Institut Paoli- Calmettes
Marseille, France
Norbert Vey, MD
Service des Maladies du Sang Hôpital Claude Huriez
Lille, France
Bruno Quesnel, MD

GERMANY
Georg-August- Universität Göttingen
Göttingen, Germany
Detlef Haase, MD, PhD
Hannover Medical School
Medizinische Hochschule Hannover
Hannover, Germany
Matthias Eder, MD, PhD
Heinrich- Heine Universität Düsseldorf
University Hospital
Düsseldorf, Germany
Ulrich Germing, MD
MDS Foundation Centers of Excellence

Johannes Gutenberg University Medical Center Mainz
Mainz, Germany
Markus Radsak, MD, PhD

Johann Wolfgang Goethe Universität Frankfurt Main, Germany
Gesine Bug, MD

Klinikum Rechts der Isar Technical University of Munich
Munich, Germany
Katrina Götte, MD

MLL Münchner Leukämielabor
Munich, Germany
Torsten Haferlach, MD
Wolfgang Kern, MD

Rems- Murr- Klinik Winnenden
Winnenden, Germany
Prof. Dr. med Markus Schaich, MD

St. Johannes Hospital Heinrich- Heine Universität
Duisburg, Germany
Carlo Aul, MD, PhD
Aristotle Giagounidis, MD, PhD

Albert- Ludwigs- Universität Freiburg
Freiburg, Germany
Michael Lübbert, MD, PhD

Universität Hamburg
Hamburg, Germany
Nicolaus Kröger, MD, PhD

Universitätsklinikum Carl Gustav Carus
Dresden, Germany
Katja Sockel, MD

University Children’s Hospital Freiburg
Freiburg, Germany
Charlotte Niemeyer, MD

University of Cologne
Cologne, Germany
Karl-Anton Kreuzer, MD

University Hospital Essen
Dept. for Hematology and Stem Cell Transplantation
Essen, Germany
Thomas Schroeder, MD

University Hospital Leipzig
Leipzig, Germany
Uwe Platzbecker, MD

University Hospital Mannheim
Mannheim, Germany
Wolf-Karsten Hofmann, MD

GREECE
Patras University Hospital
Patras, Greece
Argiris Symeonidis, MD

University of Athens Laikon Hospital
Athens, Greece
Panagiotis Diamantopoulos MD, PhD

University General Hospital Attikon
Athens, Greece
Vassiliki Pappa, MD

HUNGARY
Semmelweis University School of Medicine
Budapest, Hungary
Judit Várkonyi, MD, PhD

INDIA
Tata Medical Centre
Kolkata, India
Col(Dr.) Deepak Kumar Mishra, MD

Tata Memorial Hospital
Mumbai, India
Manju Sengar, MD

IRELAND
Adelaide and Meath Hospital
Dublin, Ireland
Helen Enright, MD

ISRAEL
Tel- Aviv Sourasky Medical Center
Tel- Aviv, Israel
Moshe Mittelman, MD

Chaim Sheba Medical Center
Tel Hashomer, Israel
Drorit Grizim Merkel, MD

ITALY
Cancer Center – IRCCS Humanitas Research Hospital
Milan, Italy
Matteo G. Della Porta, MD

Centro di Riferimento Oncologico di Basilicata (CROB)
Rionero in Vulture (PZ), Italy
Pellegrino Musto, MD

Istituto di Ematologia Università' Cattolica Sacro Cuore
Rome, Italy
Giuseppe Leone, MD

Policlinico Universitario di Roma Tor Vergata
Rome, Italy
Sergio Amadori, MD

MEXICO
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico
Alvaro Aguayo, MD

THE NETHERLANDS
Radboud University Nijmegen Medical Center
Nijmegen, The Netherlands
Saskia M.C. Langemeijer, MD

Vrije Universiteit Medical Center
Amsterdam, The Netherlands
Arjan A. van de Loosdrecht, MD, PhD

S. Eugenio Hospital Tor Vergata University
Rome, Italy
Paolo de Fabritis, MD
Pasquale Nicolia, MD

University of Florence Azienda OSP Careggi
Florence, Italy
Valeria Santini, MD

University of Pavia School of Medicine Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Mario Cazzola, MD

JAPAN
Kyoto University Hospital
Kyoto, Japan
Akiyama Takaori, MD

Metropolitan Research and Treatment Center for Blood Disorders (MRTC Japan)
Tokyo, Japan
Kiyoyuki Ogata, MD, FACP

Nagasaki University Hospital School of Medicine, Atomic Bomb Disease Institute
Nagasaki City, Japan
Yasushi Miyazaki, MD

Saitama Medical University International Medical Center
Hidaka, Saitama, Japan
Tomoyas Maeda, MD, PhD

Tokyo Medical College
Tokyo, Japan
Kazuma Ohyashiki, MD, PhD

MEXICO
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
American- British- Cowdray Cancer Center
Mexico City, Mexico
Alvaro Aguayo, MD

THE NETHERLANDS
Radboud University Nijmegen Medical Center
Nijmegen, The Netherlands
Saskia M.C. Langemeijer, MD

Vrije Universiteit Medical Center
Amsterdam, The Netherlands
Arjan A. van de Loosdrecht, MD, PhD
### MDS Foundation Centers of Excellence

<table>
<thead>
<tr>
<th>Country</th>
<th>Institution</th>
<th>City, Country</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NORWAY</td>
<td>Haukeland University Hospital</td>
<td>Bergen, Norway</td>
<td>Astrid Olsnes Kittang, MD, PhD</td>
</tr>
<tr>
<td>POLAND</td>
<td>Jagiellonian University Collegium Medicum</td>
<td>Kraków, Poland</td>
<td>Aleksander Skotnicki, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Medical University of Warsaw</td>
<td>Warsaw, Poland</td>
<td>Krzysztof Madry, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAUDI ARABIA</td>
<td>King Faisal Specialist Hospital &amp; Research Centre</td>
<td>Riyadh, Saudi Arabia</td>
<td>Amr Hanbali, MD</td>
</tr>
<tr>
<td></td>
<td>King Khaled University Hospital</td>
<td>Riyadh, Saudi Arabia</td>
<td>Ak Almomen, MD</td>
</tr>
<tr>
<td>SINGAPORE</td>
<td>Singapore General Hospital</td>
<td></td>
<td>Aloysius Ho, MD</td>
</tr>
<tr>
<td>SOUTH AFRICA</td>
<td>University of Cape Townvoid Schuur Hospital</td>
<td>Cape Town, South Africa</td>
<td>Nicolas Novitzky, MD, PhD</td>
</tr>
<tr>
<td>SOUTH KOREA</td>
<td>Catholic Blood and Marrow Transplantation Center</td>
<td>Seoul, Korea</td>
<td>Yoo-Jin Kim, MD</td>
</tr>
<tr>
<td></td>
<td>Seoul National University Hospital</td>
<td>Seoul, Korea</td>
<td>Dong Soon Lee, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Seoul National University College of Medicine</td>
<td>Seoul, Korea</td>
<td>June-Won Cheong, MD</td>
</tr>
<tr>
<td>SPAIN</td>
<td>Hospital Universitario de Salamanca</td>
<td>Salamanca, Spain</td>
<td>Maria Díez-Campelo, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Hospital Universitario La Fe</td>
<td>Valencia, Spain</td>
<td>Guillermo F. Sanz, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Vall d’Hebron Institute of Oncology</td>
<td>Barcelona, Spain</td>
<td>David Valcárcel, MD</td>
</tr>
<tr>
<td>SWEDEN</td>
<td>Karolinska Institute at Karolinska University Hospital Huddinge</td>
<td>Stockholm, Sweden</td>
<td>Eva Hellström-Lindberg, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Basel University Hospital</td>
<td>Basel, Switzerland</td>
<td>Jakob R. Passweg, MD, MS</td>
</tr>
<tr>
<td></td>
<td>Bern University Hospital and University of Bern</td>
<td>Bern, Switzerland</td>
<td>Nicolas Bonadies, MD</td>
</tr>
<tr>
<td></td>
<td>St. Clara hospital AG</td>
<td>Basel, Switzerland</td>
<td>Stefani Parmentier, MD</td>
</tr>
<tr>
<td></td>
<td>University Hospital Zurich</td>
<td>Zurich, Switzerland</td>
<td>Markus G. Manz, MD</td>
</tr>
<tr>
<td></td>
<td>Chang Gung Memorial Hospital</td>
<td>Taoyuan, Taiwan</td>
<td>Lee-Yung Shih, MD</td>
</tr>
<tr>
<td></td>
<td>Chang Gung University</td>
<td></td>
<td>Hwei-Fang Tien, MD, PhD</td>
</tr>
<tr>
<td>TAIWAN</td>
<td>National Taiwan University Hospital</td>
<td>Taipei, Taiwan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>King Chulalongkorn Memorial Hospital</td>
<td>Pathumwan, Bangkok, Thailand</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tunis, Tunisia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TUNISIA</td>
<td>Hospital Azizia Othmana</td>
<td>Tunis, Tunisia</td>
<td>Balkis Meddeeb, MD</td>
</tr>
<tr>
<td>TURKEY</td>
<td>Ankara University School of Medicine Hospital</td>
<td>Ankara, Turkey</td>
<td>Osman Ilhan, MD</td>
</tr>
<tr>
<td>UKRAINE</td>
<td>Research Center for Radiation Medicine</td>
<td>Kiev, Ukraine</td>
<td>Dimitry Bazyka, MD</td>
</tr>
<tr>
<td>UNITED KINGDOM</td>
<td>Aberdeen Royal Infirmary</td>
<td>Aberdeen University School of Medicine</td>
<td>Foresterhill, Aberdeen, Scotland</td>
</tr>
<tr>
<td></td>
<td>Cambridge University Hospitals</td>
<td>Cambridge, United Kingdom</td>
<td>Alan J. Warren, MD</td>
</tr>
<tr>
<td></td>
<td>King’s College London &amp; King’s College Hospital</td>
<td>London, United Kingdom</td>
<td>Ghulam J. Mufti, DM, FRCP, FRCPPath</td>
</tr>
<tr>
<td></td>
<td>Queen Elizabeth Hospital</td>
<td>Birmingham, United Kingdom</td>
<td>Manoj Raghavan, MD</td>
</tr>
<tr>
<td></td>
<td>St. James’s University Hospital</td>
<td>Leeds, United Kingdom</td>
<td>Catherine Cargo, MD</td>
</tr>
<tr>
<td></td>
<td>National Institute of Hematology and Blood Transfusion</td>
<td>Hanoi, Vietnam</td>
<td>Khanh Quoc Bach, MD</td>
</tr>
</tbody>
</table>
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for the Treatment of IDH1-Mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

TIBSOVO is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation

Fifth approved indication for TIBSOVO solidifies

BOSTON, MA — Oct. 24, 2023 (PRNewswire). Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced the U.S. Food and Drug Administration (FDA) has approved TIBSOVO® (ivosidenib tablets) for the treatment of patients with isocitrate dehydrogenase 1 (IDH1)-mutated relapsed or refractory (R/R) myelodysplastic syndromes (MDS). This is the fifth indication for TIBSOVO across IDH1–mutated cancers, and the first and only approved targeted therapy for people diagnosed with R/R MDS within this molecularly defined subset.

“Servier is proud to lead the way in mutant IDH1 inhibition through continued innovations that support patients living with difficult and hard-to-treat cancers,” said Arjun Prasad, Head of Commercial, Servier Pharmaceuticals. “As the first and only targeted therapy available for patients with IDH1–mutated relapsed or refractory myelodysplastic syndromes, today’s FDA approval for TIBSOVO reinforces our commitment to deliver significant advances in areas of high unmet need and bring the right treatment, to the right patient, at the right time.”

The FDA approval of this indication is supported by a pivotal Phase 1, open-label study in IDH1–mutated R/R MDS patients (n=18) where a complete remission (CR) rate of 38.9% and objective response rate (ORR) of 83.3% were documented in patients treated with TIBSOVO. In addition, the median time to CR was 1.9 months (range: 1.0, 5.6). At the time of data cutoff, the median duration of CR had not been reached (range: 1.9, 80.8+) and the median overall survival was 35.7 months (range: 3.7+, 88.7+). Additionally, of the nine patients who were transfusion dependent with red blood cells or platelets at baseline, 66.7% (n=6) became independent of transfusions during any ≥56–day post-baseline period. Overall, treatment–related adverse events were consistent with the known safety profile of TIBSOVO.

“The novel use of targeted therapy across IDH1–mutated cancers has become a powerful therapeutic option for patients within this molecularly defined subset,” said Amir Fathi, M.D., hematologist, medical oncologist, and expert in myeloid malignancies. “This new indication in IDH1–mutated relapsed or refractory myelodysplastic syndromes reinforces the importance of mutational testing to inform treatment decisions and potentially improve patient outcomes.”

An estimated 16,000 people in the U.S. are diagnosed with MDS each year. Approximately 3.6% of MDS patients have an IDH1 mutation, which is considered an early “driver” mutation. For MDS patients with an IDH1 mutation, the prognosis has often been associated with worse overall outcomes and an increased risk of transformation to AML.

“This approval for TIBSOVO is welcome news for the MDS community,” said Tracey Iraca, Executive Director, MDS Foundation. “Before today, there were no approved targeted therapies available to relapsed or refractory MDS patients harboring the IDH1–mutation. We want to thank the study participants, their families and caregivers, as well as the researchers at Servier and clinical investigators involved in this study for helping to bring a new treatment option to patients where there has been a significant unmet need.”

“An MDS diagnosis is ambiguous. I remember feeling confused trying to make sense of my diagnosis, what having an IDH1–mutation meant, and what options were available for my treatment plan,” said Susan, a patient living with IDH1–mutated MDS. “The news of an FDA approval for a targeted therapy in IDH1–mutated MDS has given me a tremendous sense of gratitude and provides hope to patients – like me – who are living with this disease. I want to thank everyone who played a role in this major step forward for the MDS community.”

TIBSOVO was granted Breakthrough Therapy designation for the treatment of adult patients with R/R (MDS) with an IDH1 mutation and received Priority Review, which accelerated the review timeline and is granted to applications for medicines that, if approved, would provide significant improvements in the effectiveness or safety of the treatment, diagnosis, or prevention of serious conditions. The FDA also approved the Abbott RealTime IDH1 Assay as a companion diagnostic device to select patients for TIBSOVO.

* Denotes a censored observation. **Last name withheld to protect privacy.

ABOUT THE NCT02074839 CLINICAL TRIAL

This Phase I, open-label multinational study evaluated the safety, tolerability, and clinical activity of ivosidenib in patients with relapsed or refractory myelodysplastic syndromes with an IDH1 mutation. The primary endpoint was complete remission (CR) plus partial remission (PR) rate and key secondary endpoints included duration of CR+PR, duration of transfusion independence, and time to transfusion independence.

ABOUT TIBSOVO® (IVOSIDENIB TABLETS)

TIBSOVO is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). TIBSOVO is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.

In the U.S., TIBSOVO is approved for the treatment of adults with IDH1–mutant relapsed or refractory AML in monotherapy or in combination with azacitidine for adults with newly diagnosed IDH1–mutant AML who are ≥75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy, as monotherapy for the treatment of adult patients with IDH1–mutant relapsed or refractory MDS, and for patients with previously treated IDH1–mutated cholangiocarcinoma.

Servier has granted CStone a co–exclusive license for the development and an exclusive license agreement for the commercialization of TIBSOVO in Mainland China, Taiwan, Hong Kong, Macao and Singapore.

For more information about TIBSOVO in the U.S., please visit www.tibsovo.com.
Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

FOSTER CITY, CA — August 21, 2023 (BUSINESS WIRE). Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS).

“The FDA’s acceptance of our New Drug Application is an important landmark along our steadfast journey to bring telomerase inhibition with imetelstat to the market,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “We look forward to continuing our collaboration with the FDA toward the goal of bringing imetelstat to the many patients for whom we believe this treatment could make a significant difference.”

“FDA acceptance of our NDA is a significant milestone for both Geron and the MDS community, as there remain few treatment options and significant unmet needs, particularly for patients with difficult-to-treat subtypes of this cancer,” said Faye Feller, M.D., Executive Vice President, Geron’s Chief Medical Officer. “We believe that the IMerge Phase 3 data reflect the truly unique attributes of imetelstat, and, if approved, we expect imetelstat will change the standard of care in lower risk MDS.”

The NDA submission is based on results from IMerge Phase 3, in which the primary endpoint of 8-week transfusion independence (TI) was significantly higher with imetelstat vs. placebo (p<0.001), with median TI duration approaching one year for imetelstat 8-week TI responders. Mean hemoglobin levels in imetelstat-treated patients increased significantly (p<0.001) over time compared to placebo patients. Statistically significant and clinically meaningful efficacy results were achieved across key MDS subgroups irrespective of ring sideroblast (RS) status, baseline transfusion burden and IPSS risk category. Patient-reported outcomes (PRO) data reported a sustained meaningful improvement in fatigue for imetelstat-treated patients vs. placebo. Safety results were consistent with prior imetelstat clinical experience.

As allowed under the 21st Century Cures Act, the FDA has up to 74 days from the NDA submission date to notify Geron of the Prescription Drug User Fee Act (PDUFA) action date for the NDA. Upon receipt of this notification, Geron plans to disclose the timeline for the NDA review.

Additionally, Geron expects to submit a Marketing Authorization Application (MAA) in the European Union (EU) in the fourth quarter of 2023.

ABOUT IMERGE PHASE 3

The Phase 3 portion of the IMerge Phase 2/3 study is a double-blind, 2:1 randomized, placebo-controlled clinical trial to evaluate imetelstat in patients with IPSS Low or Intermediate-1 risk (lower risk) transfusion dependent MDS who were relapsed after, refractory to, or ineligible for, erythropoiesis stimulating agent (ESA) treatment, had not received prior treatment with either a HMA or lenalidomide and were non-del(5q). To be eligible for IMerge Phase 3, patients were required to be transfusion dependent, defined as requiring at least four units of packed red blood cells (RBCs), over an eight-week period during the 16 weeks prior to entry into the trial. The primary efficacy endpoint of IMerge Phase 3 is the rate of red blood cell transfusion independence (RBC-TI) lasting at least eight weeks, defined as the proportion of patients without any RBC transfusion for at least eight consecutive weeks since entry to the trial (8-week TI). Key secondary endpoints include the rate of RBC-TI lasting at least 24 weeks (24-week TI), the duration of TI and the rate of hematologic improvement erythroid (HI-E), which is defined under 2006 IWG criteria as a rise in hemoglobin of at least 1.5 g/dL above the pretreatment level for at least eight weeks or a reduction of at least four units of RBC transfusions over eight weeks compared with the prior RBC transfusion burden. A total of 178 patients were enrolled in IMerge Phase 3 across North America, Europe, Middle East and Asia.

ABOUT IMETELSTAT

Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic malignancies. Data from non-clinical studies and clinical trials of imetelstat provide strong evidence that imetelstat targets telomerase to inhibit the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies resulting in malignant cell apoptosis and potential disease-modifying activity. Imetelstat has been granted Fast Track designation by the U.S. Food and Drug Administration for both the treatment of adult patients with transfusion dependent anemia due to Low or Intermediate-1 Risk MDS that is not associated with del(5q) who are refractory or resistant to an erythropoiesis stimulating agent, and for adult patients with Intermediate-2 or High-risk MF whose disease has relapsed after or is refractory to janus associated kinase (JAK) inhibitor treatment. Imetelstat is currently not approved by any regulatory authority.
COMMANDS Trial:
First-Line Luspatercept Boosts Chance of Transfusion Independence in Lower-Risk MDS

June 30, 2023. In the global phase III COMMANDS trial of patients with low-risk transfusion-dependent myelodysplastic syndrome (MDS), with or without ring sideroblasts, treatment with luspatercept essentially doubled the likelihood of achieving transfusion independence and an increase in hemoglobin level, compared with epoetin alfa, an erythropoiesis-stimulating agent (ESA), in a planned interim analysis.1

“Luspatercept is the first and only therapy to demonstrate superiority in a head-to-head study against ESAs in transfusion-dependent lower-risk MDS. This is important, as ESAs have been the first-line treatment for patients with lower-risk MDS for decades,” said Guillermo Garcia-Manero, MD, Professor in the Department of Leukemia and Chief of the Section of Myelodysplastic Syndromes at The University of Texas MD Anderson Cancer Center in Houston.

Luspatercept, an erythroid maturation agent, is approved by the U.S. Food and Drug Administration for the treatment of patients with lower-risk MDS who meet certain criteria, including the presence of ring sideroblasts and failure on (or ineligibility for) an ESA, based on the results of the MEDALIST trial.2

The subsequent global COMMANDS trial evaluated the drug in a wider population that included patients with and without ring sideroblasts. The primary endpoint was transfusion independence for at least 12 weeks within the first 24 weeks with a concurrent mean hemoglobin increase of at least 1.5 g/dL. At the time of this planned interim analysis (representing 80% of participants), 58.5% receiving luspatercept met this endpoint, compared with 31.2% receiving epoetin alfa (P<.0001), Dr. Garcia-Manero reported in a press briefing prior to the 2023 ASCO Annual Meeting.

He maintained that COMMANDS would usher in a “paradigm shift” in the treatment of patients with lower-risk MDS-associated anemia who are naive to prior therapy. “I think that’s going to happen with the presentation of these results.... They will move traditional ESAs over and establish luspatercept as front-line therapy.”

COMMANDS DETAILS

The global phase III COMMANDS clinical trial included 354 patients with lower-risk MDS as defined by the revised International Prognostic Scoring System (IPSS-R) criteria. Patients were ESA-naïve, had less than 5% bone marrow blasts and serum EPO levels less than 500 U/L, and required red blood cell transfusions (defined as 2–6 units 8 weeks for at least 8 weeks immediately prior to randomization).

Patients were randomly assigned to receive subcutaneous luspatercept (starting dose 1.0 mg/kg, titration up to 1.75 mg/kg) once every 3 weeks for at least 24 weeks (n = 178) or epoetin alfa (starting dose 450 IU/kg, titration up to 1,050 IU/kg) once a week for at least 24 weeks (n = 176). At the planned interim analysis of 301 patients, the median treatment duration was 41.6 weeks for luspatercept and 27.0 weeks for epoetin alfa.

OUTCOMES BY RING SIDEROBLAST STATUS

“For the primary endpoint, patients receiving luspatercept, regardless of subgroup, achieved transfusion independence with a hemoglobin increase,” Dr. Garcia-Manero said. The drug was effective regardless of baseline serum erythropoietin level, red blood cell transfusion burden, SF3B1 mutation status, or ring sideroblast status.

For patients with ring sideroblasts (n = 220), the primary endpoint was met by 64.8% receiving luspatercept vs 25.9% receiving the ESA. For the ring sideroblast–negative subset (n = 80), this endpoint was met by 41.0% vs 46.3%.

Dr. Garcia-Manero said the disproportionate number of patients with ring sideroblasts was the result of the more common occurrence of this phenotype and the approval of luspatercept in ring sideroblast–positive patients. “The study was not powered to see a significant difference between ESAs and luspatercept in the ring sideroblast–negative context, but the results are not inferior. Actually, they are quite similar,” he said. “Furthermore, look at the duration of response. Patients receiving luspatercept experienced longer durations of transfusion independence, regardless of ring sideroblast status.”

Median durations of transfusion independence with luspatercept vs epoetin alfa, with hazard ratios (HR) and 95% confidence intervals, follow: all patients, 126.6 vs 77.0 weeks (HR = 0.456 [CI = 0.260–0.798]); ring sideroblast–positive, 120.9 vs 47.0 weeks (HR = 0.626 [CI = 0.361–1.085]); ring sideroblast–negative: not estimable vs 95.1 weeks (HR = 0.492 [CI = 0.148–1.638]).

SECONDARY ENDPOINTS AND TOLERABILITY

The secondary endpoints in the study included hematologic improvement—erythroid response ≥8 weeks and red blood cell transfusion independence at 24 weeks and at ≥12 weeks. Across these endpoints, as with the primary endpoint, luspatercept was more effective than epoetin alfa (Table 1).

Dr. Garcia-Manero reported.

Safety was consistent with previous experience with luspatercept, according to Dr. Garcia-Manero. Adverse events were slightly more common with luspatercept (92.1%) than epoetin alfa (85.2%), as were those considered related to treatment (30.3% vs 17.6%). Treatment discontinuation occurred in 4.5% and 2.3%, respectively.

The most common grade 3 or 4 adverse events attributed to treatment with luspatercept were anemia (7.3%), thrombocytopenia (3.9%), neutropenia (3.9%), and dyspnea (3.9%). Transformation to acute myeloid leukemia was observed in 2.2% of the luspatercept arm and 2.8% of the epoetin arm. All-cause mortality was similar, 18% in each arm.

Dr. Garcia-Manero said the favorable toxicity profile, coupled with the ease of administration (every 3 weeks), “is probably why this drug, in my opinion, will likely become the standard of care for our patients with lower-risk MDS, whether they are ring sideroblast–positive or –negative. I think there will be a paradigm shift for most patients.”
MDSF Quarterly Interaction Metrics

In an effort to mathematically quantify our outreach efforts, the MDSF will now be distributing quarterly interaction metrics.

The staff at the MDS Foundation works hard to support patients and their caregivers. We work to find answers, supply educational resources, provide emotional support, and connect patients with our MDS Centers of Excellence.

The data provided has been pulled from phone inquiries, email communications, and message board posts. Patients, family & friends, and members of the community find us primarily through internet searches. The other two more commonly seen referral sources are our Centers of Excellence partners and word-of-mouth of others who have called in previously.

Although the MDSF serves as an advocate for all who reach out, we know there are still people we are missing. In our Building Blocks of Hope publication, we encourage patients to become a partner in their care. In order to do this, patients need to be fully informed on their disease and medical advances over time. As the Director of Patient Care, the highlight of my day is speaking with those impacted by MDS and helping them to decipher the available information. Please refer anyone you feel may benefit from our services to the MDSF. Contact information is listed below. Next quarterly metrics will be reviewed ~January 19, 2024.

Centers of Excellence Referrals
Dana–Farber (2); Duke (1); Fred Hutchinson (2); Johns Hopkins (1); Mayo Florida (1); Mayo Rochester (1); MD Anderson (2); Memorial Sloan-Kettering (1); Mount Sinai (1); Policlinico Tor Vergata (1); Stanford (1); Texas Oncology Austin (1); University of Alabama (1); University of Arizona (1); University of Southern California (2); University of Kansas (1); Vanderbilt (3)

Total Referrals: 23 (24.7% of those who reached out to the MDSF)

**TABLE 1. Outcomes with Luspatercept vs Epoetin Alfa**

<table>
<thead>
<tr>
<th>ENDPOINT INT</th>
<th>LUSPATERCEPT</th>
<th>EPOETIN ALFA</th>
<th>PVALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transfusion independence ≥12 weeks + hemoglobin increase*</td>
<td>58.5%</td>
<td>31.2%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HI-E response</td>
<td>74.1%</td>
<td>51.3%</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Transfusion independence ≥24 weeks</td>
<td>47.6%</td>
<td>29.2%</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Transfusion independence ≥12 weeks</td>
<td>66.7%</td>
<td>46.1%</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

*≥1.5 g/dL within the first 24 weeks.
HI-E=hematologic-erythroid improvement ≥8 weeks

DISCLOSURE: The study was funded by Bristol Myers Squibb. Dr. Garcia-Manero reported financial relationships with AbbVie, Acceleron Pharma, Astex Pharmaceuticals, Bristol Myers Squibb/Celgene, Curis, Genentech, Gilead Sciences, and Novartis.

REFERENCES
Advancing Research & Patient Care

The 18th International Congress on
Myelodysplastic Syndromes
Rotterdam, The Netherlands
7–10 May 2025

Join international MDS experts to learn about the latest advances, discoveries, basic and translational research, and MDS diagnosis, prognosis, and management.

MDS Foundation
The Myelodysplastic Syndromes Foundation, Inc.

mdsr.kenes.com